Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 9/20 | 0.52 |
| ▸ | DRD5 | P21918 | 9/20 | 0.52 |
| ▸ | DRD2 | P14416 | 8/20 | 0.52 |
| ▸ | DRD3 | P35462 | 7/20 | 0.52 |
| ▸ | DRD4 | P21917 | 5/20 | 0.50 |
| ▸ | MAOA | P21397 | 4/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616785 | 0.94 | MAOA (0.61) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL8244793 | 0.91 | MAOA (0.57) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL24228558 | 0.83 | NOTUM (0.43) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL25975984 | 0.81 | PNMT (0.46) | DRD1DRD2DRD3HRH3 | |
| SCHEMBL14500169 | 0.79 | DRD1 (0.50) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL7645219 | 0.79 | DRD2 (0.55) | DRD1DRD5DRD2DRD4NOTUM | |
| SCHEMBL18033537 | 0.79 | HRH3 (0.50) | NOTUMHRH3 | |
| SCHEMBL20939374 | 0.79 | MEN1 (0.38) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL2625792 | 0.78 | ALDH1A1 (0.50) | DRD2DRD4NOTUM | |
| SCHEMBL414198 | 0.78 | NPC1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-3932404-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-10954216-B2 | BMP-signal-inhibiting compound | RIKEN (JP) | 2021-03-23 | — | — | US | disclosed |
| WO-2021028645-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028649-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| EP-3478673-B1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-16 | — | — | EP | disclosed |
| EP-3647311-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2019-11-07 | — | — | US | disclosed |
| EP-3564232-A1 | BMP-SIGNAL-INHIBITING COMPOUND | Riken (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-20150065489-A1 | Substituted Quinolines and Their Use As Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2015-03-05 | — | — | US | disclosed |
| US-8865702-B2 | B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | disclosed |
| US-20110021488-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20100197664-A1 | NOVEL B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| WO-2009050248-A1 | SUBSTITUTED PIPERIDINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-09-06 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-7229986-B2 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | DRD1 121/4885DRD5 545/4885DRD2 67/4885 |
| US-10954216-B2 | BMP-signal-inhibiting compound | BMP1, BMP2, BMP4 | DRD1 4528/4885DRD5 4264/4885DRD2 4415/4885 |
| US-20110021488-A1 | New Compounds | ABCG2, ADORA2B, ADORA3 | DRD1 22/4885DRD5 89/4885DRD2 25/4885 |
| US-20100197664-A1 | NOVEL B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | DRD1 1395/4885DRD5 2376/4885DRD2 1205/4885 |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | BMP1, BMP2, BMPR2 | DRD1 4605/4885DRD5 4417/4885DRD2 4569/4885 |
| US-20150065489-A1 | Substituted Quinolines and Their Use As Medicaments | QARS1, RECQL, CYP3A7 | DRD1 791/4885DRD5 3681/4885DRD2 832/4885 |
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | DRD1 347/4885DRD5 447/4885DRD2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.